Clinical Trial Update: Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating vorinostat, lenalidomide, and dexamethasone in multiple myeloma refractory to prior lenalidomide-containing regimens; Phase 1/2 study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Vorinostat (vorinostat)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-21